by Truveta staff | Apr 2, 2024 | Data
A common misconception is that drugs and devices must gain explicit approval from the FDA for each specific use before healthcare providers can employ them. However, a practice known as off-label use challenges this notion, revealing a broader landscape of treatment...
by Truveta Research | Apr 2, 2024 | Research, Research Insights
There was a decrease in the rate of amphetamine/dextroamphetamine (Adderall) prescription fills per eligible population starting in the fall of 2022; prescription fill rates were 11.4% lower in the first five months of 2023 compared to the first five months of 2022....
